MX360727B - Composiciones y metodos para evitar la agregacion del vector aav. - Google Patents

Composiciones y metodos para evitar la agregacion del vector aav.

Info

Publication number
MX360727B
MX360727B MX2014006734A MX2014006734A MX360727B MX 360727 B MX360727 B MX 360727B MX 2014006734 A MX2014006734 A MX 2014006734A MX 2014006734 A MX2014006734 A MX 2014006734A MX 360727 B MX360727 B MX 360727B
Authority
MX
Mexico
Prior art keywords
aggregation
virions
aav
compositions
methods
Prior art date
Application number
MX2014006734A
Other languages
English (en)
Spanish (es)
Inventor
John Fraser Wright
Guang Qu
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35462907&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX360727(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX360727B publication Critical patent/MX360727B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Lubricants (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
MX2014006734A 2004-06-01 2005-06-01 Composiciones y metodos para evitar la agregacion del vector aav. MX360727B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57599704P 2004-06-01 2004-06-01
US63922204P 2004-12-22 2004-12-22
PCT/US2005/019235 WO2005118792A1 (en) 2004-06-01 2005-06-01 Compositions and methods to prevent aav vector aggregation

Publications (1)

Publication Number Publication Date
MX360727B true MX360727B (es) 2018-11-14

Family

ID=35462907

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2014006734A MX360727B (es) 2004-06-01 2005-06-01 Composiciones y metodos para evitar la agregacion del vector aav.
MXPA06014030A MXPA06014030A (es) 2004-06-01 2005-06-01 Composiciones y metodos para evitar la agregacion del vector aav.
MX2019006353A MX2019006353A (es) 2004-06-01 2006-11-30 Composiciones y metodos para evitar la agregacion del vector aav.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MXPA06014030A MXPA06014030A (es) 2004-06-01 2005-06-01 Composiciones y metodos para evitar la agregacion del vector aav.
MX2019006353A MX2019006353A (es) 2004-06-01 2006-11-30 Composiciones y metodos para evitar la agregacion del vector aav.

Country Status (10)

Country Link
US (4) US7704721B2 (enExample)
EP (3) EP3290513B1 (enExample)
JP (5) JP2008501339A (enExample)
BR (1) BRPI0511764B8 (enExample)
CA (1) CA2569244C (enExample)
DK (2) DK1751275T3 (enExample)
ES (2) ES2647477T3 (enExample)
HU (2) HUE060433T2 (enExample)
MX (3) MX360727B (enExample)
WO (1) WO2005118792A1 (enExample)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ576563A (en) * 2006-11-03 2012-09-28 Alphavax Inc Alphavirus and alphavirus replicon particle formulations and methods
US20090111099A1 (en) * 2007-10-27 2009-04-30 Yongsheng Ma Promoter Detection and Analysis
US8067241B2 (en) * 2009-08-26 2011-11-29 General Electric Company Method and apparatus for antigen retrieval process
PT2529020T (pt) * 2010-01-28 2018-07-30 Childrens Hospital Philadelphia Plataforma de fabrico escalável para purificação de vetor viral e vetores virais assim purificados para utilização na terapia génica
CN102985536B (zh) 2010-04-14 2017-12-05 Emd密理博公司 生产高效价、高纯度的病毒母液的方法及使用其的方法
WO2012018628A1 (en) 2010-07-26 2012-02-09 Board Of Regents, The University Of Texas System Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
WO2012122625A1 (en) * 2011-03-14 2012-09-20 National Research Council Of Canada Method of viral production in cells
JP6348064B2 (ja) 2011-11-22 2018-06-27 ザ チルドレンズ ホスピタル オブ フィラデルフィア 効率の高いトランスジーン送達のためのウイルスベクター
EP2790737B1 (en) * 2011-12-12 2018-11-21 The Children's Hospital of Philadelphia Large commercial scale lentiviral vector production system and vectors produced thereby
US9974850B2 (en) 2013-01-25 2018-05-22 Board Of Regents, The University Of Texas System Immunogenic compositions and uses thereof
HRP20181606T1 (hr) 2013-06-17 2018-11-30 De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport Postupci za sprječavanje agregacije virusnih komponenti
JP6567974B2 (ja) 2013-11-29 2019-08-28 タカラバイオ株式会社 アデノ随伴ウイルスの定量方法
CN114395559A (zh) 2014-04-25 2022-04-26 吉尼松公司 高胆红素血症的治疗
EP3151866B1 (en) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
WO2016004319A1 (en) * 2014-07-02 2016-01-07 University Of Florida Research Foundation, Inc. Compositions and methods for purifying recombinant adeno-associated virus
BR112017009497A2 (pt) 2014-11-05 2018-02-06 Voyager Therapeutics, Inc. polinucleotídeos de aadc para o tratamento da doença de parkinson
US10570395B2 (en) 2014-11-14 2020-02-25 Voyager Therapeutics, Inc. Modulatory polynucleotides
CA2967367C (en) 2014-11-14 2023-05-16 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
HK1245326A1 (zh) 2014-12-12 2018-08-24 Voyager Therapeutics, Inc. 用於生产scaav的组合物和方法
WO2016114992A2 (en) * 2015-01-13 2016-07-21 Alfa Wassermann, Inc. Methods of purifying adeno-associated virus (aav) and/or recombinant adeno-associated virus (raav) and gradients and flow-through buffers therefore
EP3054007A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
EP3368054A4 (en) 2015-10-28 2019-07-03 Voyager Therapeutics, Inc. REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV)
SG11201804166YA (en) 2015-11-16 2018-06-28 Res Inst Nationwide Childrens Hospital Materials and methods for treatment of titin-based myopathies and other titinopaties
EP4215605A1 (en) * 2015-12-11 2023-07-26 The Trustees of The University of Pennsylvania Scalable purification method for aav8
HUE061100T2 (hu) 2016-03-28 2023-05-28 Ultragenyx Pharmaceutical Inc Adenovírus hõinaktiválásának módszerei
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
JP7066635B2 (ja) 2016-05-18 2022-05-13 ボイジャー セラピューティクス インコーポレイテッド 調節性ポリヌクレオチド
RU2764587C2 (ru) 2016-05-18 2022-01-18 Вояджер Терапьютикс, Инк. Способы и композиции для лечения хореи гентингтона
US20190284576A1 (en) * 2016-07-21 2019-09-19 Spark Therapeutics, Inc. SCALABLE HIGH RECOVERY METHODS FOR PRODUCING HIGH YIELD RECOMBINANT ADENO-ASSOCIATED VIRAL (rAAV) VECTOR AND RECOMBINANT ADENO-ASSOCIATED VIRAL (rAAV) VECTORS PRODUCED THEREBY
EP3510161A4 (en) 2016-08-23 2020-04-22 Akouos, Inc. COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING DEFICIENCY IN A HUMAN SUBJECT
US11298041B2 (en) 2016-08-30 2022-04-12 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
EP3293203A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293260A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293259A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
AU2017322376B2 (en) 2016-09-12 2023-08-17 Association Institut De Myologie Acid-alpha glucosidase variants and uses thereof
EP3512939A1 (en) 2016-09-16 2019-07-24 Leukocare AG A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
PL3534922T3 (pl) 2016-11-04 2024-08-19 Takeda Pharmaceutical Company Limited Preparaty wirusa związanego z adenowirusem
US10626376B2 (en) 2016-11-14 2020-04-21 St. Jude Children's Research Hospital Method for isolating and purifying adeno-associated virus particles using salt
US10294452B2 (en) * 2016-11-22 2019-05-21 Dao-Yao He Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
US11357735B2 (en) 2017-02-01 2022-06-14 Centre National De La Recherche Scientifique Particles and compositions comprising the same for transfection
EP3592848A1 (en) 2017-03-10 2020-01-15 Genethon Treatment of glycogen storage disease iii
SG11201909868YA (en) 2017-05-05 2019-11-28 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP7229989B2 (ja) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド 軌道アレイガイドシステム
AU2018311069A1 (en) 2017-08-03 2020-02-20 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
EP3687582A4 (en) 2017-09-29 2021-07-14 Voyager Therapeutics, Inc. RESCUE OF CENTRAL AND PERIPHERAL NEUROLOGICAL PHENOTYPE OF FRIEDREICH ATAXIA BY INTRAVENOUS ADMINISTRATION
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
EP3707264A1 (en) 2017-11-08 2020-09-16 Avexis Inc. Means and method for preparing viral vectors and uses of same
JP2021505610A (ja) * 2017-12-05 2021-02-18 アプライド ジェネティック テクノロジーズ コーポレイション ウイルス粒子のための製剤最適化
SG11202006722RA (en) 2018-01-31 2020-08-28 Res Inst Nationwide Childrens Hospital Gene therapy for limb-girdle muscular dystrophy type 2c
JP7467356B2 (ja) 2018-02-07 2024-04-15 ジェネトン ハイブリッド調節要素
US20210010028A1 (en) 2018-03-06 2021-01-14 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
AU2019257755A1 (en) 2018-04-27 2020-11-12 Voyager Therapeutics, Inc. Methods for measuring the potency of AADC viral vectors
JP2021523914A (ja) 2018-05-15 2021-09-09 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． パーキンソン病を治療するための組成物および方法
WO2019222441A1 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
WO2019222444A2 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Directed evolution
US12228571B2 (en) 2018-06-08 2025-02-18 Novartis Ag Cell-based assay for measuring drug product potency
EP3814514A1 (en) 2018-06-29 2021-05-05 Research Institute at Nationwide Children's Hospital Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a
SG11202012044QA (en) 2018-06-29 2021-01-28 Wuhan Neurophth Biological Tech Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
CA3103963A1 (en) 2018-07-02 2020-01-09 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
US20210163990A1 (en) * 2018-07-11 2021-06-03 Baxalta Incorporated Aav compositions
US20210355454A1 (en) 2018-07-24 2021-11-18 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
CA3107572A1 (en) 2018-08-08 2020-02-13 Genethon Mini-gde for the treatment of glycogen storage disease iii
AU2019319976B2 (en) * 2018-08-10 2025-08-14 Regenxbio Inc. Scalable method for recombinant AAV production
AU2019323434A1 (en) 2018-08-20 2021-02-25 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
EP3856762A1 (en) 2018-09-28 2021-08-04 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
TW202035689A (zh) 2018-10-04 2020-10-01 美商航海家醫療公司 測量病毒載體粒子的效價及強度之方法
SG11202107645RA (en) 2019-01-18 2021-08-30 Voyager Therapeutics Inc Methods and systems for producing aav particles
US12377170B2 (en) 2019-02-26 2025-08-05 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery of β-sarcoglycan and the treatment of muscular dystrophy
CN113747926A (zh) 2019-04-08 2021-12-03 吉尼松公司 用于肌肉表达的杂合启动子
TW202103718A (zh) * 2019-04-19 2021-02-01 美商銳進科斯生物股份有限公司 腺相關病毒載體調配物及方法
BR112021020888A2 (pt) 2019-04-19 2021-12-21 Genethon Terapia gênica de doenças hipofosfatêmicas relacionadas a fator de crescimento fibroblástico 23
TW202106879A (zh) 2019-04-29 2021-02-16 美商航海家醫療公司 於生物反應器中生產經桿狀病毒感染之昆蟲細胞(biic)之系統及方法
EP4004213A1 (en) 2019-07-25 2022-06-01 Novartis AG Regulatable expression systems
WO2021030125A1 (en) 2019-08-09 2021-02-18 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
EP4013436A1 (en) 2019-08-14 2022-06-22 Leukocare Ag Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
US11155835B2 (en) 2019-08-19 2021-10-26 The Catholic University Of America Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells
US11401530B2 (en) 2019-08-19 2022-08-02 The Catholic University Of America Bacteriophage-based artificial viruses for human genome remodeling
DK4017871T5 (da) 2019-08-21 2024-08-05 Res Inst Nationwide Childrens Hospital Adenoassocieret virusvektoradministration af alfa-sarcoglycan og behandling af muskeldystrofi
EP4022070A1 (en) 2019-08-26 2022-07-06 Voyager Therapeutics, Inc. Controlled expression of viral proteins
AU2020362119A1 (en) 2019-10-07 2022-05-26 Regenxbio Inc. Adeno-associated virus vector pharmaceutical composition and methods
WO2021078834A1 (en) 2019-10-22 2021-04-29 Genethon Chimeric acid-alpha glucosidase polypeptides and uses thereof
CN114555808A (zh) 2019-10-22 2022-05-27 吉尼松公司 嵌合多肽及其用途
CN113025633B (zh) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
KR102167829B1 (ko) * 2020-02-10 2020-10-20 주식회사 이노테라피 아데노연관바이러스용 안정화제 및 이를 이용한 아데노연관바이러스의 안정화 방법
WO2021168362A1 (en) 2020-02-21 2021-08-26 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
WO2021236908A2 (en) 2020-05-20 2021-11-25 Biomarin Pharmaceutical Inc. Use of regulatory proteins for the production of adeno-associated virus
EP3913060A1 (en) 2020-05-22 2021-11-24 Genethon Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapy
CA3185729A1 (en) * 2020-06-02 2021-12-09 Janssen Biotech, Inc. Materials and methods for viral purification
EP4192514A1 (en) 2020-08-06 2023-06-14 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
AU2021320395A1 (en) * 2020-08-07 2023-04-13 Janssen Biotech, Inc. Formulations for highly purified viral particles
EP4200410A1 (en) 2020-08-24 2023-06-28 Genethon C-terminal truncated gde for the treatment of glycogen storage disease iii
AU2021372262B9 (en) 2020-11-02 2025-05-15 Biomarin Pharmaceutical Inc. Process for enriching adeno-associated virus
CA3199661A1 (en) 2020-12-09 2022-06-16 Mario Amendola Lysosomal acid lipase variants and uses thereof
US20240141378A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20240141377A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20240240204A1 (en) * 2021-05-07 2024-07-18 Board Of Regents, The University Of Texas System Methods and compositions for transport, storage, and delivery of adeno-associated viral vector and other molecules
WO2023012313A1 (en) 2021-08-04 2023-02-09 Genethon Hybrid promoters for gene expression in muscles and in the cns
EP4402265A1 (en) 2021-09-16 2024-07-24 Novartis AG Novel transcription factors
US12285497B2 (en) 2021-10-15 2025-04-29 Research Institute At Nationwide Children's Hospital Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
WO2023073526A1 (en) 2021-10-25 2023-05-04 Novartis Ag Methods for improving adeno-associated virus (aav) delivery
EP4511392A1 (en) 2022-03-17 2025-02-26 Innoskel Polynucleotides encoding the alpha-1 chain of human type ii collagen and methods of their use
WO2023175585A1 (en) 2022-03-17 2023-09-21 Innoskel Hybrid promoters and their use in osteolysis syndrome
CN118974284A (zh) 2022-05-06 2024-11-15 诺华股份有限公司 新型重组aav vp2融合多肽
WO2023237731A1 (en) 2022-06-09 2023-12-14 Genethon N-terminal truncated gde for the treatment of glycogen storage disease iii
WO2024054983A1 (en) 2022-09-08 2024-03-14 Voyager Therapeutics, Inc. Controlled expression of viral proteins
TW202426017A (zh) * 2022-11-24 2024-07-01 俄羅斯聯邦商拜奧卡德聯合股份公司 非包膜病毒的藥物組合物
WO2025003477A1 (en) 2023-06-29 2025-01-02 Genethon N-terminal truncated glycogen debranching enzymes for the treatment of glycogen storage disease iii
EP4606892A1 (en) 2024-02-23 2025-08-27 Merck Patent GmbH Methods for the production of viral particles

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE420977B (sv) * 1976-03-18 1981-11-16 Kabi Ab Forfarande for rening och isolering av hepatitvirus for vaccinframstellning
US6194191B1 (en) * 1996-11-20 2001-02-27 Introgen Therapeutics, Inc. Method for the production and purification of adenoviral vectors
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6566118B1 (en) * 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
EP1080218A1 (en) * 1998-05-27 2001-03-07 University of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient
CA2399321C (en) * 2000-03-07 2013-04-30 Robert K. Evans Adenovirus formulations
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
ES2285120T3 (es) * 2002-05-14 2007-11-16 MERCK & CO., INC. Procedimientos de purificacion de adenovirus.

Also Published As

Publication number Publication date
ES2932278T3 (es) 2023-01-17
JP5769650B2 (ja) 2015-08-26
WO2005118792A1 (en) 2005-12-15
JP2019058177A (ja) 2019-04-18
EP3290513B1 (en) 2022-09-07
JP2016195587A (ja) 2016-11-24
HUE060433T2 (hu) 2023-03-28
BRPI0511764A (pt) 2008-01-08
EP1751275A4 (en) 2008-01-23
US20110076744A1 (en) 2011-03-31
JP2012143233A (ja) 2012-08-02
CA2569244A1 (en) 2005-12-15
US20170247664A1 (en) 2017-08-31
US20160083694A1 (en) 2016-03-24
MXPA06014030A (es) 2007-10-08
EP1751275B1 (en) 2017-08-16
JP2014111625A (ja) 2014-06-19
BRPI0511764B1 (pt) 2017-10-24
EP1751275A1 (en) 2007-02-14
EP4170024A1 (en) 2023-04-26
JP2008501339A (ja) 2008-01-24
EP3290513A1 (en) 2018-03-07
US9051542B2 (en) 2015-06-09
DK3290513T3 (da) 2022-12-12
DK1751275T3 (da) 2017-11-27
ES2647477T3 (es) 2017-12-21
CA2569244C (en) 2017-02-14
BRPI0511764B8 (pt) 2021-05-25
US7704721B2 (en) 2010-04-27
MX2019006353A (es) 2022-06-27
US20060035364A1 (en) 2006-02-16
HUE035418T2 (en) 2018-05-02

Similar Documents

Publication Publication Date Title
MX360727B (es) Composiciones y metodos para evitar la agregacion del vector aav.
KR102181658B1 (ko) 바이러스 함유 제형 및 이의 용도
US7456009B2 (en) Adenovirus formulations
ES2683330T3 (es) Desinfectante de la piel basado en peróxido de hidrógeno
US7351415B2 (en) Adenovirus formulations
Lynch et al. Biopolymer mediated trehalose uptake for enhanced erythrocyte cryosurvival
WO2010100200A3 (en) Lyophilised antibody formulation
KR20090114411A (ko) 보존 안정성이 뛰어난 광역 항바이러스 약제 조성물
AU2016204371A1 (en) Lyophilised and aqueous anti-CD40 antibody formulations
EP2968112B2 (en) Stable aqueous formulations of adenovirus vectors
WO2012015810A2 (en) Pharmaceutical compositions containing pemetrexed having extended storage stability
JP2017537910A5 (enExample)
CL2008003762A1 (es) Composicion concentrada en suspension acuosa para proteccion de cultivos, que comprende un compuesto activo y como agentes estabilizadores, un disperzante no ionico y un dsipersante anionico y agua; metodos para preparacion de dicha composicion y usos de la misma, para el cuidado de cultivos de interes.
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
US20080112932A1 (en) Methods and reagents for the enhancement of virus transduction in the bladder epithelium
GEP20115217B (en) Aqueous active ingredient concentrate having an herbicidal effect
Guo et al. Brincidofovir is a robust replication inhibitor against African swine fever virus in vivo and in vitro
CA3003960A1 (en) Transduction buffer
CN113201484A (zh) 改进牛体外受精囊胚冻存和解冻的方法
EA200702593A1 (ru) Высококонцентрированные композиции, применимые для борьбы с экто- и эндопаразитами
WO2005066333A1 (en) Stabilizing compositions for recombinant viruses
PE20230514A1 (es) Composiciones farmaceuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio
WO2010019276A3 (en) Method and formulation for treating adverse biological conditions
GB9716611D0 (en) Virus preparations and methods
JPWO2016181975A1 (ja) タンパク質凝集防止剤